Drug Data Drives Genocea Biosciences Inc (GNCA) Higher

Upbeat data on Genocea Biosciences Inc's (GNCA) genital herpes drug has the stock blazing higher

Mar 31, 2016 at 10:32 AM
facebook twitter linkedin

Genocea Biosciences Inc (NASDAQ:GNCA) is the biggest gainer on the Nasdaq this morning, blowing up on positive mid-stage trial data on its genital herpes treatment. At last check, the biotech stock has jumped almost 26% to hover at $5.01 -- vaulting it above its 140-day moving average for the first time since August.
Today's bullish gap could have short sellers sweating bullets. Short interest rose more than 10% during the past two reporting periods to roughly 2.4 million shares -- the highest level ever. Now, nearly 11% of GNCA's float is sold short, which would take over three weeks to cover, at the stock's typical trading volume.

It's a far different story among the brokerage bunch. All five analysts following GNCA consider it worthy of a "buy" or better rating. Plus, the stock's consensus 12-month price target of $13 represents a brow-raising 159% premium to current levels.

Today's gains aside, Genocea Biosciences Inc (NASDAQ:GNCA) is a long-term technical laggard. Its year-to-date loss is 5%. Worse yet, since the stock topped out at an annual peak of $16.18 in July, GNCA has surrendered roughly 69% of its value.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners